Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

BRCA gene mutations and ovarian cancer: an interview with Dr Matulonis, Harvard Medical School

The BRCA gene encodes for the BRCA proteins, BRCA1 and BRCA2. These proteins are very important in repairing DNA, which they do by correcting double-stranded breaks.

2 Aug 2015

FDA accepts Mundipharma EDO's Investigational New Drug Application for EDO-S101

Mundipharma EDO GmbH (Early Development in Oncology) is pleased to announce that the United States Food and Drug Administration has accepted the company's Investigational New Drug Application ("IND") for EDO-S101, a fusion molecule to treat relapsed/refractory haematologic malignancies and solid tumours.

31 Jul 2015

VolitionRx selects Global Specimen Solutions to support U.S. market entry of NuQ colorectal cancer tests

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that it has engaged the services of a specialty specimen management clinical research organization, Global Specimen Solutions, Inc., to support initial U.S. market entry of its NuQ colorectal cancer tests.

28 Jul 2015

Protein imbalances within cells can cause ovarian cancer

Cancer can be caused solely by protein imbalances within cells, a study of ovarian cancer has found. The discovery is a major breakthrough because, until now, genetic aberrations have been seen as the main cause of almost all cancer.

28 Jul 2015

New computer algorithm helps scientists see drug's activity inside the body

Researchers at Columbia University Medical Center have developed a computer algorithm that is helping scientists see how drugs produce pharmacological effects inside the body. The study, published in the journal Cell, could help researchers create drugs that are more efficient and less prone to side effects, suggest ways to regulate a drug's activity, and identify novel therapeutic uses for new and existing compounds.

24 Jul 2015

Important new target identified for ovarian cancer therapy

Scientists at Lawson Health Research Institute have uncovered an important new target for ovarian cancer therapy. Contrary to current research this new study found that LKB1, a molecule that regulates the metabolism of many adult cells, is an important molecule in the cancer's promotion and survival.

23 Jul 2015

NeoGenomics announces launch of new germline cancer predisposition testing services

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today the launch of a new line of germline cancer predisposition testing services. The new tests include comprehensive testing for BRCA1 and BRCA2 encompassing an analysis of all exons and adjacent intronic regions.

20 Jul 2015

Novogen's Anisina granted FDA Orphan Drug Designation for neuroblastoma

US-Australian drug discovery company, Novogen Limited, today announced that it has received notification from the U.S. Food and Drug Administration that its chemotherapy candidate drug, Anisina, has been granted Orphan Drug Designation for neuroblastoma.

16 Jul 2015

Study: Breast cancer survivors experience post-treatment weight gain compared with cancer-free peers

Among women with a family history of breast cancer, those diagnosed with breast cancer gained weight at a greater rate compared with cancer-free women of the same age and menopausal status.

15 Jul 2015

Cedars-Sinai's groundbreaking online registry improves participation in clinical research

Research for Her, Cedars-Sinai's groundbreaking online registry that matches women with research studies and clinical trials, enrolled study participants more quickly when compared with traditional paper-based registries, according to new research published in the journal Gynecologic Oncology.

14 Jul 2015

Study shows that Anisina has potential to improve effectiveness of chemotherapy in children with cancer

US-Australian drug discovery company, Novogen Limited, today announced details of an in vivo proof of concept study that demonstrates their lead anti-tropomyosin drug candidate, Anisina, has the potential to improve the effectiveness of chemotherapy in children and reduce life-long side-effects.

14 Jul 2015

Molecular cancer expert David Livingston named recipient of Basser Global Prize

The Basser Center for BRCA at Penn's Abramson Cancer Center has announced the recipient of its third annual Basser Global Prize. The honor will go to molecular cancer expert David Livingston, MD, Emil Frei Professor of Genetics and Medicine at Harvard Medical School, and deputy director of the Dana-Farber/Harvard Cancer Center.

10 Jul 2015

Huntsman Cancer Institute receives NCI's Comprehensive Cancer Center designation

The National Cancer Institute has awarded Huntsman Cancer Institute at the University of Utah its Comprehensive Cancer Center status, the highest designation possible.

9 Jul 2015

Ludwig, CRI launch clinical trials to evaluate immunotherapies for treatment of GBM and solid tumors

Ludwig Cancer Research and the Cancer Research Institute have launched clinical trials evaluating an immunotherapy for the treatment of the brain cancer glioblastoma multiforme (GBM), and a combination of immunotherapies for a variety of solid tumors.

8 Jul 2015

Tests reveal that FY26 cancer drug is 49 times more potent than Cisplatin drug

Tests have shown that a new cancer drug, FY26, is 49 times more potent than the clinically used treatment Cisplatin.

7 Jul 2015

ImmunoCellular, Novella partner to conduct ICT-107 phase 3 registration trial in patients with glioblastoma

ImmunoCellular Therapeutics, Ltd. today announced the establishment of an agreement with Novella Clinical (Novella), to conduct the phase 3 registration trial of ICT-107 in patients with newly diagnosed glioblastoma. Novella is a full-service, global clinical research organization (CRO) providing clinical trial services to small to mid-sized oncology companies.

6 Jul 2015

Paclitaxel-fostamatinib combination therapy may reduce size of ovarian cancer cells

Working in cell cultures and mice, researchers at Johns Hopkins have found that an experimental drug called fostamatinib combined with the chemotherapy drug paclitaxel may overcome ovarian cancer cells' resistance to paclitaxel.

2 Jul 2015

PharmaMar begins PM1183 phase III study in patients with platinum-resistant ovarian cancer

PharmaMar announced today the start of a phase III study for the anticancer agent PM1183 in patients with platinum-resistant ovarian cancer (PROC). Once study objectives are met, the CORAIL trial (NCT02421588) will be used to support the regulatory filing of PM1183 as treatment for this indication.

30 Jun 2015

The Mary Kay Foundation awards $1.3 million grant to advance cancer research and discovery

With more than 800,000 new cases of cancer among women in the United States expected this year, according to the American Cancer Society, almost everyone is touched by the disease.

27 Jun 2015

No overall survival benefit for bevacizumab in ovarian cancer

Addition of bevacizumab to first-line platinum-based chemotherapy does not improve overall survival in women with ovarian cancer, according to the mature data of the ICON7 trial.

26 Jun 2015

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

BRCA gene mutations and ovarian cancer: an interview with Dr Matulonis, Harvard Medical School

FDA accepts Mundipharma EDO's Investigational New Drug Application for EDO-S101

VolitionRx selects Global Specimen Solutions to support U.S. market entry of NuQ colorectal cancer tests

Protein imbalances within cells can cause ovarian cancer

New computer algorithm helps scientists see drug's activity inside the body

Important new target identified for ovarian cancer therapy

NeoGenomics announces launch of new germline cancer predisposition testing services

Novogen's Anisina granted FDA Orphan Drug Designation for neuroblastoma

Study: Breast cancer survivors experience post-treatment weight gain compared with cancer-free peers

Cedars-Sinai's groundbreaking online registry improves participation in clinical research

Study shows that Anisina has potential to improve effectiveness of chemotherapy in children with cancer

Molecular cancer expert David Livingston named recipient of Basser Global Prize

Huntsman Cancer Institute receives NCI's Comprehensive Cancer Center designation

Ludwig, CRI launch clinical trials to evaluate immunotherapies for treatment of GBM and solid tumors

Tests reveal that FY26 cancer drug is 49 times more potent than Cisplatin drug

ImmunoCellular, Novella partner to conduct ICT-107 phase 3 registration trial in patients with glioblastoma

Paclitaxel-fostamatinib combination therapy may reduce size of ovarian cancer cells

PharmaMar begins PM1183 phase III study in patients with platinum-resistant ovarian cancer

The Mary Kay Foundation awards $1.3 million grant to advance cancer research and discovery

No overall survival benefit for bevacizumab in ovarian cancer

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in